Zymergen–ZY-NYSE – went public in early May 2021 via IPO led by Goldman Sachs and JP Morgan at $30 per share. It dutifully rose to $48 on such esteemed backing.
- Zero revenues? Check.
- Huge TAM? (bio-manufacturing platform) Check.
- Bleeding cash? Check. 10x 2023 revenue estimates? Check.
- “Cheap” to high growth peers? Check.
- Glowing sell-side reports by the underwriters? Check
In what might truly be a record in my brain, it took 4 months for the comeuppance: delays, no revenue in 2021, CEO resignation.
To paraphrase without a celebrity or lizard, “So what’s in your portfolio?”